That's, 6,385,150 shares.
Google article title if interested, "Steve Cohen’s Point72 Asset Management Just Reported Giant Ironwood Pharmaceuticals Inc Stake"
Besides, I will always pick a drug company headquartered in close proximity to MIT, Harvard, and Mass. General Hospital over one headquartered in close proximity to Metro North, The Oyster Bar, and Bellevue.
Dream on. IRWD and their partners are investing major money into advertising to build a dominant position in the CIC market. In the process of bringing this drug to market, they have racked up losses of about a billion dollars. Why would they want to start that process over again? Besides, only the rosiest interpretation of the plecanatide trial would suggest that the drug is superior to Linzess. Their partisans seem to have seized on the somewhat lower incidence of diarrhea -which could easily be explained by the fact that plecanatide just doesn't work that well. Which is why the higher dose seems to work no better than the lower dose. And why both doses barely outperform the placebo. (Or as one reviewer of Linzess put it, "I have some diarrhea, but when you are suffering from constipation, that's not necessarily a bad thing.") PS: SGYP is projected to lose $150 million over the next year and a half. Everyone wants a piece of THAT action.
It's not unthinkable. Plecanatide is a vastly better drug but IRWD, thanks to its Linzess experience, is the perfect marketer. It would be a near-seamless handoff.
By contrast, no deal leads IRWD with no product. It will be unable to compete. New IRWD drugs are years off.
What should IRWD pay for SGYP? I think $30 per share. Pre-plecanatide, IRWD (which owned just half the rights to Linzess) was selling $15-16 a share. 100% ownership of plecanatide ought to be double that share amount.
Not as risky as some, apparently. Since July 30, when this poster was in ecstasy about the wonderful trial numbers published by Synergy, that stock has fallen from 9.60 to 7. IRWD is up half a buck, even after the big biotech dump. Yep.
Yes, Motley Fool posits that if everything works out, the SGYP drug MIGHT be on the market at the end of next year. Linzess got FDA approval 3 years ago, and although it's superior to Amitiza, it has taken them this long to build a larger market share. If the SGYP drug was clearly superior to Linzess - which it's not - it might get a bit of traction by 2019. I find it interesting that you somehow garner two "thumbs up"s for this semiliterate nonsense. ("artical"? And you should realize that verbs are an essential element of sentence structure.)
motley fool artical this morning reporting irwd days are numbered due to sgyp gold class drug. thats why they pumping linzess bigtime
Which suggests to me that the stock is under accumulation. The burgeoning sales of Linzess seem to have finally caught the market's attention. The fact that it is quickly replacing Amitiza makes profitability less of an issue. They are using consumer advertising to effectively drive sales. If the company were to be acquired and the management and marketing costs rolled into another organization, they would become instantly profitable.